Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

These devices are increasingly popular in diabetes management and health monitoring. As previously announced, Trinity Biotech has entered into a non-binding Letter of Intent with Bayer for the launch ...

Senseonics (NYSE:SENS) is set to bring the longest-lasting continuous glucose monitor (CGM) to market following a major ...

Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...

CGM devices use a small filament inserted under the skin, usually on the back of the upper arm or abdomen, to continuously measure glucose levels in interstitial fluid. The CGM wirelessly ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on ...

Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy be ...

As previously announced, Trinity Biotech has entered into a non-binding Letter of Intent with Bayer for the launch of a CGM device in China and India. As part of this, Trinity Biotech is launching ...